Tommy Andersson

Tommy Andersson


Personal profile


Our studies are focused on the revelation of WNT5A, a secreted glycoprotein. WNT5A belongs to the non-transforming class of WNTs, and upon binding to different receptors or co-receptor complexes (Frizzled, RYK, ROR1/2, LRP5/6 and CD146), it elicits non-canonical (β-catenin-independent) signaling. WNT5A act as both tumor promoter as well as tumor suppressor, depending on cell type. For example, in breast cancer loss of WNT5A protein is associated with poor survival. In contrast, WNT5A expression is associated with increased metastasis and reduced survival in melanoma patients.  Our laboratory focusses on how WNT5A expression is regulated in these cancers and deciphering the WNT5A signaling pathways governing cancer cell migration and invasion.
On therapeutic front, we have developed a hexapeptide, Foxy5 (an agonist of WNT5A) which is currently in Phase1 clinical trial for breast cancer, prostate cancer and colon carcinoma (NCT02020291). Another peptide, Box5 (a WNT5A derived antagonist) is currently in pre-clinical trials for malignant melanoma.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

UKÄ subject classification

  • Cancer and Oncology

Free keywords

  • WNT5A
  • Melanoma
  • Breast Cancer


Dive into the research topics where Tommy Andersson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or